Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Pacific Biosciences of California Is Collapsing Today

By Brian Feroldi - Dec 15, 2016 at 11:46AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares crater in response to the news that Roche has decided to terminate its partnership agreement with the company.

Image source: Getty Images.

What happened

Shares of Pacific Biosciences of California ( PACB -6.12% ), a small-cap healthcare company focused on genomic sequencing, fell by more than 38% as of 10:40 a.m. EST on Thursday. The decline is directly attributable to the news that healthcare giant Roche Holdings ( RHHBY -0.55% ) has decided to terminate its partnership agreement with the company. 

So what

Roche and Pacific Biosciences' agreement was originally signed in 2013. The deal allowed Roche to develop diagnostic products based on Pacific Biosciences' SMRT technology and sell them worldwide. Meanwhile, Pacific Biosciences maintained its right to market its products for all fields outside of human in vitro diagnostics. 

This agreement also granted Roche the right to walk away from the deal for any reason. News broke today that Roche's management team has decided to exercise that option.

Here's what Dr. Michael Hunkapiller, Pacific Biosciences' CEO, had to say about the news: 

The clinical research and sequencing market and regulatory environment have evolved during the three years since we entered into this agreement with Roche. While we are disappointed with Roche's decision to terminate the agreement, we are already familiar with this market and Roche's decision does not significantly change our near-term plans for expanding our business to address this market.

Shares of Pacific Biosciences tumbled in early-morning trading on the news.

Now what

There's no doubt that Roche's decision to walk away from Pacific Biosciences raises huge questions about the company's future. After all, Roche is a massive company with resources that far exceed that of Pacific Biosciences, and many investors believed that this relationship would bear fruit for years to come. Roche's decision to terminate the deal pours cold water on that thesis.

If you are looking for a bright side here, it is worth pointing out that Pacific Biosciences continues to believe that its near-term outlook is looking bright. Management reaffirmed that its product and service revenue is on pace to grow more than 55% in 2016. What's more, Pacific Biosciences believes that its revenue will grow by another 40% to 60% in 2017.

That's all great, but since this news raises new questions about the company's long-term future, I think approaching this stock with caution is likely to be the right way to go.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$49.24 (-0.55%) $0.27
Pacific Biosciences of California, Inc. Stock Quote
Pacific Biosciences of California, Inc.
PACB
$20.24 (-6.12%) $-1.32

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
640%
 
S&P 500 Returns
139%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.